Chris LaGanke

Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

Edward Fox, Keith R. Edwards, Gordon Burch et al. · Multiple Sclerosis and Related Disorders · 2014 · 77 citations

Pharmacy, Pharmacotherapy, Outcomes Research +10

Cladribine tablets added to IFN-β in active relapsing MS

Xavier Montalbán, Thomas Leist, Bruce A. Cohen et al. · Neurology Neuroimmunology & Neuroinflammation · 2018 · 63 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +12

Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

Molly Perkins, Caroline F. Ryschkewitsch, Julia C. Liebner et al. · PLoS Pathogens · 2012 · 51 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY)

Stanley Cohan, Harold Moses, Jonathan Calkwood et al. · Multiple Sclerosis and Related Disorders · 2018 · 51 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17